J&J, states settle on Risperdal

Share this article:

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

These include misusing CME programs for marketing; awarding grants to doctors based on prescribing habits; presenting information that is not scientifically sound; and disseminating reprints with off-label usage information.

At press time, J&J was expected to pay up to $2.2 billion for the same allegations by DOJ involving these and other drugs.

On its website, J&J said it's not admititng any Risperdal wrongdoing.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions